Atypical hus associated with severe, unexpected antibody-mediated rejection post kidney transplant

Nephrology

Volumn 19, Issue , 2014, Pages 22-26

  Stevenson, Sarah ^a   Mallett, Andrew ^b   Oliver, Kimberley ^a   Hyland, Valentine ^b   Hawley, Carmel ^a   De Malmanche, Theo ^c   Isbel, Nicole ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Alternative complement pathway; Antibody mediated rejection; Atypical HUS; Eculizumab; Haemolytic anaemia; Kidney transplantation; Microangiopathic transplant nephrectomy

Indexed keywords

ANTIBODY;

ADULT; CASE REPORT; COMPLICATION; FEMALE; GRAFT REJECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATION; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES; ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; SEVERITY OF ILLNESS INDEX;

EID: 84921945959     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12195     Document Type: Review

References (10)

1. de Jorge EG, Macor P, Paixao-Cavalcante D et al. The development of atypical haemolytic uremic syndrome depends on complement C5. J. Am. Soc. Nephrol. 2011; 22: 137–45.
2. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical haemolytic and uremic syndrome. Am. J. Transplant. 2013; 3: 663–75.
3. Bresin E, Rurali E, Caprioli J et al. Combined complement gene mutations in atypical haemolytic uremic syndrome influence clinical phenotype. J. Am. Soc. Nephrol. 2013; 24: 475–86.
4. Caprioli J, Norris M, Brioschi S et al., International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: The impact of MCP, CFH and IF mutaions on clinical presentation, response to treatment and outcome. Blood 2006; 108(4): 1267–79.
5. Loirat C, Niadudet P. The risk of recurrence of haemolytic uremic syndrome after renal transplantation in children. Pediatr. Nephrol. 2003 Nov; 18(11): 1095–101.
6. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant haemolytic uremic syndrome. Nat. Rev. Nephrol. 2011; 7: 23–35.
7. Le Quintrec M, Lionet A, Kramer N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am. J. Ttransplant. 2008 Aug; 8(8): 1694–701.
8. Noone D, Al-Matrafi J, Tinckam K et al. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with Eculizumab. Am. J. Transplant. 2012; 12: 2546–53.
9. Stegall M, Chedid M, Cornell L. The role of complement in antibody-mediated rejection in kidney transplantation. Nat. Rev. Nephrol. 2012; 8: 670–78.
10. Stegall M, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 2011; 11: 2405–13.